# Use of the test-negative design to estimate the protective effect of a scalar

- 2 immune measure: A simulation analysis
- 3 **Authors**: Ziyuan Zhang<sup>1</sup>, Christopher Brian Boyer<sup>1</sup>, Marc Lipsitch<sup>1,2\*</sup>
- 4 Affiliations:

- <sup>1</sup> Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.
- 6 Chan School of Public Health, Boston, Massachusetts, USA
- 7 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- 8 Health, Boston, Massachusetts, USA
- 9 \* Correspondence: Marc Lipsitch, DPhil, Center for Communicable Disease Dynamics,
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington
- Avenue, Boston, MA 02115, USA. (mlipsitc@hsph.harvard.edu).

### Abstract

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

**Background**: The relationship between antibody levels (more generally, a scalar measure of immune protection) at the time of exposure to infection (so-called exposure-proximal correlates of protection) and the risk of infection given exposure is of central interest in evaluating the evolution of immune protection conferred by prior infection and/or vaccination. A version of the test-negative study design (TND), adapted from vaccine effectiveness studies, has been used to assess this relationship. However, the conditions under which such a study identifies the relationship between immune measurements and protection have not been defined. **Objective**: To evaluate the conditions for TNDs to estimate the relationship between antibody levels or a similar scalar measurement of immunity (hereafter exposure-proximal correlates of protection, COP) and the relative incidence rate of infection given exposure. **Method:** Individual-based transmission models, linking infection risk linearly and nonlinearly with COP value and accounting for waning immunity post-vaccination and -infection, were used. Simulations were performed of a TND with sampling on predetermined dates. Data from either one or multiple simulation days were analyzed using logistic regression and generalized additive models. **Result**: A correctly specified logistic regression model provided an unbiased estimate of the effectiveness of specific COP levels (analogous to vaccine effectiveness). Aggregating data across different simulation dates with incidence-density sampling also provided reliable estimates of protection. When, as is generally the case, the functional form relating COP level to protection is unknown, generalized additive models offer a more flexible alternative to traditional logistic regression approaches.

**Conclusion**: A TND can validly estimate the relative effect of an immune COP at the time of exposure on the incidence rate of infection via logistic regression if the functional form of the effect is known and appropriately modeled or unknown a semiparametric approach. Future research should further examine the dynamics of immunity waning and boosting for more reliable inference.

### 1. Introduction

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Correlates of protection (COP) are measurable quantities such as binding or neutralizing antibody concentrations that predict the degree of protection against incidence of an infectious disease. These markers provide valuable insights into the immune system's response to pathogens and vaccines. Which is essential for advancing the understanding of immune mechanisms, as well as facilitating estimates of levels of protection in the population over time and informing the evaluation of new vaccines. For example, hemagglutination-inhibition antibody titers have been identified as a COP for influenza.<sup>2,3</sup> COP are particularly useful for estimating vaccine effectiveness by linking the magnitude of an immune response to levels of protection, especially in scenarios where direct measures of effectiveness are not available. 4,5 Recent studies highlight the importance of post-immunization antibody titers as effective COP for COVID-19 vaccines.<sup>6,7</sup> Notable research efforts have investigated the use of these correlates to forecast absolute risks (AR) and relative risks (RR) of infection in randomized vaccine efficacy trials, 4,6,8–10 using the antibody concentration measured at a fixed time postvaccination. More recently, an observational study using a test-negative design (TND) was employed to estimate "exposure-proximal" COP, that is, how the COP level around the time an individual may be exposed to infection affects their risk of becoming infected.<sup>11,12</sup> The use of the TND for exposure-proximal COP studies builds on a longstanding tradition of using these studies, which compare vaccination histories of those who test positive for a condition (e.g., COVID-19) with those experiencing the same symptoms but testing negative for the condition, to evaluate vaccine effectiveness. If the vaccine provides all-ornothing protection and there are no unmeasured confounding with respect to infection or testseeking, such as due to heterogeneous vaccination decisions or characteristics leading to varying

susceptibility among participants, the odds ratio (OR) for vaccination among test-positive vs. test-negative participants in a TND is an unbiased estimator of the incidence rate ratio (IRR) in the population, such that one minus the OR estimates vaccine effectiveness (1-IRR). These assumptions are strong, <sup>13</sup> and methodological work has highlighted that they may be violated in practice. <sup>14–20</sup>

However, to our knowledge, no study has yet evaluated the validity of the TND for monitoring the relationship between a continuous exposure-proximate COP and protection. In contrast with using the TND for vaccine effectiveness, the goal is not to estimate the causal effect, as interventions on the correlate may not be well defined, but rather to estimate the (predictive) relationship between COP-level and infection over time. In this case, our main concern is the potential for selection bias due to the sampling scheme of the TND.

Here, we introduce a novel, simplified simulation model that mimics disease transmission within a community, taking into account vaccination and the waning immunity from previous infections, to explore whether the TND is able to recover the relationship between COP and infection and to identify the correct transformations and statistical models for accurately linking COP to infection. We are specifically interested in situations where assessing vaccine effectiveness in TND may otherwise introduce bias such as when the vaccine exhibits leaky protection. When the relationship between COP, the predictor, and infection risk is linear, we show that a model linking the ln(IRR) of infection to either the logarithm of one minus the linear predictor of incidence rate (parametric) or a flexible function of that predictor (semiparametric) can effectively recover the correct relationship between that predictor and the incidence rate ratio of infection. When the relationship is unknown, we show semiparametric methods are superior.

### 2. Methods

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

## 2.1 Simulation model and assumptions

We employed an individual-based transmission model, involving susceptible, exposed, asymptomatically infectious, symptomatically infectious, vaccinated, and recovered individuals, to simulate disease transmission within a community (Figure 1), with detailed parameters listed in **Table 1**. Individuals were tracked because each individual had a level of a scalar measure of immunity, denoted as X, that varied over time and affected their risk of becoming infected. The model made several key assumptions: The risk of infection decreases linearly as the individual's COP level increases, calculated as  $\beta * (I - X) * (I + A)/N$ , where  $\beta$  is the transmission coefficient, X is a rescaled COP level ranging from 0 to 1, I is the number of symptomatically infectious individuals, A is the number of asymptomatically infectious individuals, and N is the total population. One third of the infectious individuals are assumed to be symptomatic and this proportion did not vary over time or across subgroups.<sup>21</sup> We assume COP provides equal protection against asymptomatic and symptomatic infection. Individuals cannot receive vaccinations if they are symptomatically infectious. All susceptible individuals start with a COP level at 0 units, and a first-time exposure, including recovery after infection or vaccination, will raise the COP level from 0.00 to 0.75 units. With subsequent exposures, this level will boost from current level to 1 unit. These specific values act as simplified indicators to assess the degree of protection conferred against infections following the first<sup>22,23</sup> and subsequent<sup>24–26</sup> exposures, respectively. Additionally, all uninfected individuals experience a linear immunity decline at a rate of 0.01 units per day, modeled as a simplified waning mechanism, whereas exposed and infectious individuals will remain their antibody level unchanged until they recover. <sup>27–30</sup> Data on each individual's antibody level and infection status is recorded on predetermined simulation

dates. In the simulation, 0.5% of the eligible population will be vaccinated every 15 days from day 1 to day 600, totaling 40 rounds. By the end, 20% of the eligible population will receive the vaccine.




Figure 1. Schematic representation of the model<sup>a</sup>

<sup>a</sup> For detailed descriptions of the parameters used, refer to **Table 1**.

**State**: S, Susceptible; E, Exposed; I, Symptomatically Infectious; A, Asymptomatically

Infectious; R, Recovered; V, Vaccinated.

108

109

110

111

112

113

114

115116

117

118119

**Arrow**: Solid arrows represent continuous transitions between states; dashed arrows represent the discrete vaccination schedule as detailed in Methods.

## Table 1. Model parameters

Parameter	Description	Value
N	Population size	50,000
tlatent	Latent period	5 <sup>31</sup>
tinfectious	Infectious period	7 <sup>32</sup>
α	Symptomatically infectious proportion	1/3 <sup>21</sup>
σ	Rate from exposed to infectious	1 / t <sub>latent</sub>
γ	Rate from infectious to recovered	1 / tinfectious
R <sub>0</sub>	Basic reproduction number	$2^{33}$
β	Transmission coefficient	$R_0$ / $t_{infectious}$
λ	Per capita rate of infection	$\beta$ * no. of infectious people
W	Antibody level waning rate	0.01
Initial S	No. of initial susceptible cases	48,950
Initial E	No. of initial exposed cases	25
Initial I	No. of initial infectious cases	25
Initial R	No. of initial recovered cases	1000

### 2.2 Data sampling scheme

In our simulation, we implemented a data sampling scheme modeled after a typical TND study.<sup>34</sup> Symptomatically infectious individuals were identified as cases, and each case was matched with four controls who were susceptible, recovered, or exposed. This sampling scheme implies selection of controls is independent of COP level on that day. It was assumed that all symptomatically infectious individuals tested positive, and the matched controls tested negative.

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

odds.

To increase sample size by aggregating data across multiple days, we used an incidence density sampling approach, matching cases and controls based on the day of sampling. 2.3 Statistical analysis Our analysis considered four regression models: two logistic regression models (with and without transformation of the independent variable, the COP measurement X) and two generalized additive models (GAMs, with and without transformation of X). COP levels were assessed at the time of sampling, reflecting the exposure-proximate COP — the levels measured when individuals tested positive or negative. Untransformed models modeled *logit*  $(p) \sim X$  for logistic regression and  $logit(p) \sim GAM(X)$  for the GAM, while transformed models considered  $logit(p) \sim ln(1-X)$ for the transformed logistic regression and logit  $(p) \sim GAM(ln(1-X))$  for the transformed GAM. The rationale for the transformation was as follows: The transformation applied to these levels was the natural logarithm of 1 – COP level, ln(1-x), which is used to reflect the log of IRR expression in our model setting when comparing the infection incidence rate at a specific COP level to the rate at zero COP level. The derivation is as follows:  $ln(IRR) = ln\{[\lambda * I(t) *$  $U(t) * (1 - X_{X=x})]/[\lambda * I(t) * U(t) * (1 - X_{X=0})] = ln(1 - x)$  where  $\lambda$  is the force of infection, I(t) is the number of infectious individuals at time t, and U(t) is the number of uninfected individuals at time t. Following the logic of TND vaccine studies, in which the OR provides an unbiased estimate of the IRR of infection among vaccinated versus unvaccinated individuals, <sup>13</sup> we posited that the log of IRR is linearly related to the log OR comparing individuals with a given level of COP to those who have a COP value of zero and hence the log

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

those with higher COP levels.

Further, the two different infection risk functions—squared ( $risk = \beta * (1 - X^2) * I/N$ ) and cubic ( $risk = \beta * (1 - X^3) * I/N$ ) transformations of the COP level—were sensitivity analyses used to assess the robustness of the approach to estimating the shape of the relationship between the COP value and incidence when the relationship is more complex and nonlinear. 35,36 For each of the parametric and semiparametric methods, three models are applied: an untransformed misspecified model, a transformed misspecified model, and a transformed correctly specified model. In both the misspecified and correctly specified transformed models, a natural logarithmic transformation is used. The misspecified transformed models apply linear COP levels, consistent with the primary analysis, while the correctly specified models use squared and cubic COP levels to align with the corresponding infection risk functions. 3. Results The model simulated the spread of infection over 600 days within a community of 50,000 individuals. Figure 2 shows the temporal dynamics of infectious-and-symptomatic prevalence, COP level proportions, and odds of infection stratified by COP levels. Four complete waves of infection occurred. Notably, declines in the number of individuals with higher antibody levels, due to waning immunity, preceded the emergence of subsequent infection waves. As expected, the simulation shows lower mean and variability in infection odds and lower amplitudes among




Figure 2. Trends in infectious prevalence, COP proportions, and odds of infection<sup>a</sup> from simulation days 10 to 600 with an increment of 10

<sup>a</sup> The odds of infection curves are fitted using cubic splines with 15 degrees of freedom.

Panel A: the prevalence of infectious individuals. Panel B: the distribution of the population across different antibody intervals. Panel C: the odds of incident infection by COP intervals.

TND sampling from the simulation showed that when using data collected from a single day, the transformed logistic model accurately recovered the linear relationship between COP level and IRR. In contrast, the untransformed logistic model failed to do so due to misspecification of the functional form (**Figure 3**). Although both semiparametric GAM models generally captured the relationship, they often deviated from the true pattern, particularly at extreme COP values (**Figure 3A**). **Figure 3B** illustrates the relationships predicted by these models using compiled incidence density data sampled over multiple days, showing that both GAM models produced results more closely aligned with those of the transformed logistic model.




Figure 3. COP level and infection incidence rate ratio sampling on a single simulation day and compiled simulation days

Panel A used data collected from simulation day 600, panel B used data from simulation days 500-600 with an increment of 10.

The impact of population-level antibody distribution and the aggregation of data from multiple days on the accuracy of regression models in predicting infection IRR were investigated. Besides the transformed logistic regression, both GAMs accurately estimate the IRR when sufficient data are aggregated from multiple days using incidence-density sampling (Figure 4D). This accuracy is achieved during periods when the pandemic has stabilized after an extended onset, resulting in a diverse and adequately distributed range of COP levels. In situations with more limited numbers of participants with certain COP levels (Figure 4A, C) or insufficient data (Figure 4A, B) from TND sampling, semiparametric approaches tend to produce more complex estimated relationships, likely due to overfitting the noise in the data. In contrast, the transformed logistic regression consistently recovers the linear relationship.




Figure 4. Impact of antibody distribution<sup>a</sup> and data aggregation on infection incidence rate ratio predictions by regression models

<sup>a</sup> Gray areas in the plots indicate the proportions of COP levels within the population. **Panel A** used data collected from simulation day 50, **panel B** used data collected from simulation days 50-150 with an increment of 10, and **panel D** used data from simulation days 400-500 with an increment of 10.

The sensitivity analyses examined the predictability of models on the nonlinear relationships between infection risk and COP levels, including squared and cubic, with sufficient data sampled. The curves generated from the correctly specified transformed logistic regression models are capturing the true relationships, as the primary analysis did, which further shows the robustness of the model selection and transformation function. Although the semiparametric models (whether transformed, correctly specified, or not) did not capture the exact relationship at

all levels of COP, they closely approximate the true relationship with only slight fluctuations around the actual lines (**Figure 5**).




Figure 5. Sensitivity Analysis – COP level and infection incidence rate ratio sampling on compiled simulation days 500 to 600 with an increment of 10

**Panel A** used data from simulation where infection risk correlates with squared COP level, and **panel B** used data from simulation where infection risk correlates with cubic COP level.

225 Formulas used for **Panel A** include:

Untransformed Misspecified Logit:  $logit(p) \sim X$ 

Transformed Misspecified Logit:  $logit(p) \sim ln(1-X)$ 

228 Transformed Logit:  $logit(p) \sim ln(1 - X^2)$ 

229 Untransformed Misspecified GAM:  $logit(p) \sim GAM(X)$ 

Transformed Misspecified GAM:  $logit(p) \sim GAM(1-X)$ 

Transformed GAM:  $logit(p) \sim GAM(1 - X^2)$ 

#### 4. Discussion

217

218

219

221

222

223224

226

227

230

231232

233

234

235

236

237

238

239

240

Antibody levels have been used in prior studies to predict the infection risk of influenza and COVID-19, and are considered one of the appropriate COP for investigating the relationship between infection and individual immunity. However, apart from one recent paper designed for cohort studies,<sup>11</sup> there has been little work to define approaches for estimating exposure-proximate COP, that is how an individual's instantaneously measured level of immunity predicts their susceptibility to infection at that moment. While prospective cohorts have many advantages, case-control designs such as the TND are widely employed due to their

comparatively low cost and feasibility. Thus, we sought to understand the conditions under which a TND would validly estimate the relationship between a COP level and the degree of protection offered by that level.

Our study demonstrates that a TND-style approach can identify the shape of a predictive relationship between a correlate of protection measured near the time of exposure and the risk of infection when using a semiparametric model or when using a correctly specified parametric model with appropriate transformation of the value of the correlate. We have phrased this in terms of prediction rather than causal inference because it is difficult to envision even a hypothetical intervention that would set an individual's COP value at a certain level, and because for many practical purposes, prediction is the question of interest: how well protected is an individual, given a particular COP value? In a causal setting one would also have to consider confounding in which a predictor of COP value had a causal effect on the likelihood of infection. For example, if occupation were predictive of vaccination (and thus COP level) and outcome, or in vaccine campaigns where elderly or immunocompromised individuals are prioritized for early uptake and exhibit lower protection at the same COP value. We have used a model in which such common causes do not exist.

Borrowing from the theory of TNDs, the OR estimates the IRR for a particular covariate value. In the simulation, we define the risk of infection as one minus the immunity level. Therefore, in a logistic regression framework, the right-hand side, ln(IRR) or ln(1-COP), should estimate the left-hand side ln(odds), and our simulations confirm that using this functional form produces estimates that are indistinguishable from the input to the simulation. Alternatively, using a generalized additive model can approximate this relationship if one does not know the proper functional form for the relationship of the COP value to the IRR.

In TND, estimating the 'vaccine direct effect' for leaky vaccines—those that confer only partial protection to all recipients—is problematic and tends to show declining protection over time. The bias arises because vaccinated individuals continue to experience infections at a reduced rate, while unvaccinated individuals may gain immunity through natural infection. 

Over time, this dynamic narrows the infection rate gap between vaccinated and unvaccinated groups, causing the OR to trend toward the null. This pattern fails to accurately reflect the vaccine's true effectiveness. In contrast, this study shows that examining immunity levels as a predictor of infection incidence rate does not suffer from this bias. By analyzing infection rate at varying levels of COP, this approach measures how immunity, regardless of its source, influences infection likelihood. Since it does not rely solely on vaccination status, using COP levels sidesteps the specific biases introduced by leaky vaccine effects in TND. This method, therefore, offers a framework for understanding how incremental COP levels may influence infection incidence rates, while minimizing the impact of vaccine-specific assumptions.

The utilization of simulation models stands out as a major strength of this study, allowing us to emulate real-life pandemic scenarios with a degree of control over experimental variables and pre-assumed infection relative risk functions that are not typically possible in field studies. This approach enabled us to systematically test different infection IRR functions, both linear and nonlinear, and to assess their impact on the relationship between immunity levels and infection risks. Additionally, by employing several logistic regression models on the results obtained from TND, we have enhanced the robustness and applicability of our findings to actual pandemic conditions. Despite its strengths, our study is not without limitations. The infection IRR and risk functions used were intentionally simplified, which might have affected the granularity and generalizability of our findings. Similarly, the model simplifies assumptions about immunity

boosting and waning, which may not fully capture the complexities of immunity development and decline in diverse populations. Prior studies suggest that immunity waning could be nonlinear, 35,36 indicating that the model might overlook important variations. Furthermore, the assumption of homogeneity among agents—considering them to have identical susceptibility and transmission characteristics—may not truly reflect the variability observed in real populations. 37

Future research should aim to incorporate more realistic infection IRR and risk functions and more sophisticated mechanisms for modeling immunity waning and boosting. Additionally, enhancing the model by calibrating it with real-world data that includes detailed agent characteristics and distributions of COP among circulating variants of concern could significantly improve the model's accuracy and relevance. Such advancements are important for developing more effective epidemiological models, which, in turn, can inform public health strategies and vaccination programs more accurately.

#### **5. Conclusion**

Antibody levels are vital in epidemiological research, serving as a key metric for evaluating how these COP are associated with infections under various study designs. These insights are crucial for assessing vaccine efficacy and guiding public health interventions. This study shows that employing logistic regression models with natural logarithm transformations of infection IRR function helps to model the relationship between infection incidence rate and antibody levels more precisely, enabling the visualization of both linear and nonlinear effects. To enhance model accuracy, it is essential to refine infection IRR and risk functions and integrate mechanisms of immunity waning and boosting given vaccination or infection within these models. Calibration with real-world data is crucial to confirm model accuracy and relevance. By transitioning from basic theoretical frameworks to more sophisticated, data-driven models, researchers can more

effectively simulate the complex interplay between pathogen exposure, immune response, and population health outcomes, advancing the understanding of immunity dynamics and improving the capacity to predict and manage infectious diseases.

310

311

#### References

- 1. Plotkin SA. Correlates of Protection Induced by Vaccination. *Clin Vaccine Immunol*.
- 315 2010;17(7):1055-1065. doi:10.1128/CVI.00131-10
- 316 2. Black S, Nicolay U, Vesikari T, et al. Hemagglutination Inhibition Antibody Titers as a
- 317 Correlate of Protection for Inactivated Influenza Vaccines in Children. *Pediatr Infect Dis J.*
- 318 2011;30(12):1081-1085. doi:10.1097/INF.0b013e3182367662
- 3. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza Hemagglutination-
- 320 Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. *J Infect Dis.*
- 321 2011;204(12):1879-1885. doi:10.1093/infdis/jir661
- 4. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective
- 323 correlate for COVID-19 vaccines. *Vaccine*. 2021;39(32):4423-4428.
- 324 doi:10.1016/j.vaccine.2021.05.063
- 5. Khoury DS, Schlub TE, Cromer D, et al. Correlates of Protection, Thresholds of Protection,
- and Immunobridging among Persons with SARS-CoV-2 Infection. *Emerg Infect Dis.*
- 327 2023;29(2):381-388. doi:10.3201/eid2902.221422
- 328 6. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-
- 329 1273 COVID-19 vaccine efficacy clinical trial. *Science*. 2022;375(6576):43-50.
- 330 doi:10.1126/science.abm3425
- 7. Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and
- protection against a SARS-CoV-2 infection. J Infect. 2022;84(2):248-288.
- 333 doi:10.1016/j.jinf.2021.09.013
- 334 8. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- 335 asymptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(11):2032-2040.
- 336 doi:10.1038/s41591-021-01540-1
- 337 9. Goldblatt D, Fiore-Gartland A, Johnson M, et al. Towards a population-based threshold of
- 338 protection for COVID-19 vaccines. *Vaccine*. 2022;40(2):306-315.
- 339 doi:10.1016/j.vaccine.2021.12.006
- 340 10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive
- of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.*
- 342 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
- 343 11. Nilles EJ, Paulino CT, de St Aubin M, et al. Tracking immune correlates of protection for
- emerging SARS-CoV-2 variants. Lancet Infect Dis. 2023;23(2):153-154.
- 345 doi:10.1016/S1473-3099(23)00001-4
- 346 12. Huang Y, Follmann D. Exposure proximal immune correlates analysis. *Biostatistics*.
- Published online August 14, 2024:kxae031. doi:10.1093/biostatistics/kxae031

- 348 13. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of Vaccine Direct Effects
- 349 Under the Test-Negative Design. *Am J Epidemiol*. 2018;187(12):2686-2697.
- 350 doi:10.1093/aje/kwy163
- 351 14. Endo A, Funk S, Kucharski AJ. Bias correction methods for test-negative designs in the
- presence of misclassification. *Epidemiol Infect*. 2020;148:e216.
- 353 doi:10.1017/S0950268820002058
- 354 15. Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on
- observational studies of influenza vaccine effectiveness. *Vaccine*. 2015;33(11):1313-1316.
- 356 doi:10.1016/j.vaccine.2015.01.069
- 357 16. De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to
- differential and non-differential disease- and exposure misclassification in studies of vaccine
- effectiveness. Hozbor DF, ed. *PLOS ONE*. 2018;13(6):e0199180.
- 360 doi:10.1371/journal.pone.0199180
- 17. Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for causality:
- lessons from vaccine effectiveness and impact studies. *Int J Epidemiol*. Published online July
- 363 24, 2016:dyw124. doi:10.1093/ije/dyw124
- 364 18. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative
- 365 Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol*.
- 366 2016;184(5):345-353. doi:10.1093/aje/kww064
- 367 19. Westreich D, Hudgens MG. Invited Commentary: Beware the Test-Negative Design. Am J
- 368 *Epidemiol.* 2016;184(5):354-356. doi:10.1093/aje/kww063
- 369 20. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine
- 370 Effectiveness: A Systematic Review of Methodology. *Epidemiology*. 2020;31(1):43-64.
- 371 doi:10.1097/EDE.0000000000001116
- 372 21. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A
- 373 Systematic Review. *Ann Intern Med.* 2021;174(5):655-662. doi:10.7326/M20-6976
- 22. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection.
- 375 Lancet Infect Dis. 2022;22(1):12-14. doi:10.1016/S1473-3099(21)00676-9
- 376 23. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth
- against SARS-CoV-2 one year after infection. *Nature*. 2021;595(7867):426-431.
- 378 doi:10.1038/s41586-021-03696-9
- 379 24. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19
- Vaccination and Previous Infection. *N Engl J Med*. 2022;386(13):1207-1220.
- 381 doi:10.1056/NEJMoa2118691

- 382 25. Glück V, Grobecker S, Köstler J, et al. Immunity after COVID-19 and vaccination: follow-
- up study over 1 year among medical personnel. *Infection*. 2022;50(2):439-446.
- 384 doi:10.1007/s15010-021-01703-9
- 385 26. Abbasi J. Study Suggests Lasting Immunity After COVID-19, With a Big Boost From
- 386 Vaccination. *JAMA*. 2021;326(5):376. doi:10.1001/jama.2021.11717
- 387 27. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid
- 388 Immunity to SARS-CoV-2. *N Engl J Med*. 2022;386(23):2201-2212.
- 389 doi:10.1056/NEJMoa2118946
- 390 28. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe
- 391 Disease by Covid-19 Vaccines. *N Engl J Med*. 2022;386(4):340-350.
- 392 doi:10.1056/NEJMoa2115481
- 393 29. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine
- in Israel. N Engl J Med. 2021;385(24). doi:10.1056/NEJMoa2114228
- 395 30. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA
- 396 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care
- 397 Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron
- 398 Variant Predominance VISION Network, 10 States, August 2021–January 2022. MMWR
- 399 *Morb Mortal Wkly Rep.* 2022;71(7):255-263. doi:10.15585/mmwr.mm7107e2
- 400 31. Xin H, Li Y, Wu P, et al. Estimating the Latent Period of Coronavirus Disease 2019
- 401 (COVID-19). Clin Infect Dis. 2022;74(9):1678-1681. doi:10.1093/cid/ciab746
- 402 32. Ma S, Zhang J, Zeng M, et al. Epidemiological parameters of coronavirus disease 2019: a
- 403 pooled analysis of publicly reported individual data of 1155 cases from seven countries.
- 404 Published online March 24, 2020. doi:10.1101/2020.03.21.20040329
- 405 33. Locatelli I, Trächsel B, Rousson V. Estimating the basic reproduction number for COVID-19
- 406 in Western Europe. Khudyakov YE, ed. *PLOS ONE*. 2021;16(3):e0248731.
- 407 doi:10.1371/journal.pone.0248731
- 408 34. Feldstein LR, Self WH, Ferdinands JM, et al. Incorporating Real-time Influenza Detection
- Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time
- 410 Test-negative Design (rtTND). *Clin Infect Dis*. 2021;72(9):1669-1675.
- 411 doi:10.1093/cid/ciaa1453
- 412 35. Pérez-Alós L, Armenteros JJA, Madsen JR, et al. Modeling of waning immunity after SARS-
- 413 CoV-2 vaccination and influencing factors. *Nat Commun.* 2022;13(1):1614.
- 414 doi:10.1038/s41467-022-29225-4
- 36. Ghosh SK, Ghosh S. A mathematical model for COVID-19 considering waning immunity,
- vaccination and control measures. Sci Rep. 2023;13(1):3610. doi:10.1038/s41598-023-
- 417 30800-y

37. Bushman M, Kahn R, Taylor BP, Lipsitch M, Hanage WP. Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. *Cell*. 2021;184(26):6229-6242.e18. doi:10.1016/j.cell.2021.11.026

418

419

420